
The meta-analysis of five randomized trials (2,039 patients) found no significant differences between aflibercept biosimilars and reference aflibercept in improving best-corrected visual acuity, reducing retinal thickness, or minimizing CNV leakage. Adverse event rates were also similar. These findings support the use of biosimilars as cost-effective, clinically equivalent alternatives for managing neovascular age-related macular degeneration.
Like
Save
Share